Proton pump inhibitors (PPIs) may be linked to concentration and memory problems in individuals with a history of breast cancer.
As we head into a new year, Drug Topics® is exploring some of the latest pharmacy trends and how they will shape the industry in the next decade.
Solriamfetol (Sunosi, Jazz Pharmaceuticals) to treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea was approved on March 20, 2019.
The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.
Let’s take a look at some of the most common issues pharmacists are facing, as seen recently on Facebook.
Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications.
The impact of herpes zoster can be measured in a number of different ways.
The NACDS and NCPA praised the United States Supreme Court's decision to hear a case involving states’ regulation of pharmacy benefit managers.
The FDA Committees voted against recommending approval of Nektar Therapeutics' oxycodegol.
Novavax’s recombinant quadrivalent flu vaccine candidate (NanoFlu) is being evaluated in an ongoing phase 3 clinical study for use in older adults.